Cullinan Therapeutics Inc (CGEM) Stock Price, Quote & News

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its deve...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 410 4650

Website: cullinantherapeutics.com

Address:

One Main Street, Suite 1350, Cambridge, United States

d_risk Nov. 6 at 4:14 PM

$CGEM - Cullinan Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CGEM warns that challenges enrolling patients have delayed trials and could further stall or block clinical progress and regulatory approvals. #Biotechnology #DrugDevelopment #PatientEnrollment #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/CGEM/10-Q/2025-11-06

0 · Reply

mago69 Nov. 3 at 10:21 AM

$CGEM this IS a posible pump and dump for scamers to Facebook groups

0 · Reply

__SquuezedChronometer_ Nov. 2 at 11:56 AM

Next major retail squeeze candidate right here $BLND $PLTK $CGEM $CCCC

0 · Reply

lasoto3 Oct. 31 at 5:12 PM

$CGEM ummmmm

0 · Reply

lasoto3 Oct. 28 at 1:07 PM

$CGEM 🔥🔥🔥

0 · Reply

bassman4444 Oct. 25 at 8:38 PM

$CGEM What is everyone thinking here?

1 · Reply

stick_to_stocks Oct. 24 at 8:11 PM

$CGEM not always is so easy.....

0 · Reply

WycklyTrader Oct. 24 at 7:40 PM

$CGEM QNCX potential base breakout with upcoming FDA catalysts. DCB momentum watch: $PMI $RANI $VTYX $ARCT ...

0 · Reply

lasoto3 Oct. 24 at 3:17 PM

$CGEM 🔥🔥🔥

0 · Reply

lasoto3 Oct. 24 at 2:15 PM

$CGEM there it is

0 · Reply

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:11 AM EST - 4 days ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Oct 25, 2025, 11:01 AM EDT - 13 days ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Oct 17, 2025, 7:01 AM EDT - 21 days ago

Cullinan Therapeutics: Worthy Of A Small Position

Oct 13, 2025, 12:46 PM EDT - 25 days ago

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Oct 12, 2025, 6:27 PM EDT - 26 days ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Sep 12, 2025, 7:00 AM EDT - 2 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:50 AM EDT - 2 months ago

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 5:30 AM EDT - 2 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Aug 21, 2025, 4:05 PM EDT - 2 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2025, 7:00 AM EDT - 3 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 10:24 PM EDT - 4 months ago

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

Jun 4, 2025, 4:02 PM EDT - 5 months ago

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Jun 1, 2025, 8:21 AM EDT - 5 months ago

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

May 29, 2025, 7:00 AM EDT - 5 months ago

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

May 22, 2025, 5:15 PM EDT - 6 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

May 8, 2025, 7:00 AM EDT - 6 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 6 months ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

Apr 23, 2025, 10:14 AM EDT - 7 months ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Apr 16, 2025, 7:00 AM EDT - 7 months ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Feb 27, 2025, 7:00 AM EST - 9 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 7:00 PM EST - 10 months ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Jan 9, 2025, 11:11 PM EST - 10 months ago

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Jan 8, 2025, 5:26 PM EST - 10 months ago

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Nov 14, 2024, 10:01 AM EST - 1 year ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 14, 2024, 4:15 AM EDT - 1 year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Jun 1, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

May 24, 2024, 8:00 AM EDT - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 5:04 PM EDT - 1 year ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Apr 24, 2024, 10:09 AM EDT - 1 year ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Apr 16, 2024, 6:59 AM EDT - 1 year ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$

Mar 1, 2024, 7:00 AM EST - 1 year ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cullinan Oncology to Participate in Upcoming Investor Conferences

Dec 18, 2023, 4:53 PM EST - 2 years ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 4:30 PM EST - 2 years ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Nov 8, 2023, 7:00 AM EST - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:01 PM EDT - 2 years ago

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Sep 11, 2023, 11:57 AM EDT - 2 years ago

Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

$Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma$

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Aug 3, 2023, 4:15 PM EDT - 2 years ago

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Jun 28, 2023, 9:08 AM EDT - 2 years ago

Cullinan Oncology: Playing 'Moneyball' In The Drug Development Sector

d_risk Nov. 6 at 4:14 PM

0 · Reply

mago69 Nov. 3 at 10:21 AM

$CGEM this IS a posible pump and dump for scamers to Facebook groups

0 · Reply

__SquuezedChronometer_ Nov. 2 at 11:56 AM

Next major retail squeeze candidate right here $BLND $PLTK $CGEM $CCCC

0 · Reply

lasoto3 Oct. 31 at 5:12 PM

$CGEM ummmmm

0 · Reply

lasoto3 Oct. 28 at 1:07 PM

$CGEM 🔥🔥🔥

0 · Reply

bassman4444 Oct. 25 at 8:38 PM

$CGEM What is everyone thinking here?

1 · Reply

stick_to_stocks Oct. 24 at 8:11 PM

$CGEM not always is so easy.....

0 · Reply

WycklyTrader Oct. 24 at 7:40 PM

$CGEM QNCX potential base breakout with upcoming FDA catalysts. DCB momentum watch: $PMI $RANI $VTYX $ARCT ...

0 · Reply

lasoto3 Oct. 24 at 3:17 PM

$CGEM 🔥🔥🔥

0 · Reply

lasoto3 Oct. 24 at 2:15 PM

$CGEM there it is

0 · Reply

lasoto3 Oct. 24 at 2:01 PM

$CGEM in small as of this morning. Let’s wait and see.

0 · Reply

theBigDollarski Oct. 24 at 1:57 PM

$CGEM done loading here.....see you at 12 or higher in a month or two.

0 · Reply

lasoto3 Oct. 22 at 9:13 PM

$CGEM looking

0 · Reply

BuyThemCheapStackemDeep Oct. 20 at 5:30 PM

$CGEM healthy price targets coming in

0 · Reply

ChartChartist Oct. 20 at 1:38 AM

$BCG looks like everyones slapping at 4am to start the week off banking $CGEM hot $AXTI 4 bottom $AISP to 5.5 $ABL 50ma overhead

0 · Reply

BuyThemCheapStackemDeep Oct. 17 at 7:36 PM

$CGEM Just a matter of time IMO. PaYtience

0 · Reply

IntegrityEquities Oct. 17 at 2:23 PM

$CGEM u gotta be fckng kidding me

1 · Reply

Winning_calls Oct. 16 at 2:20 PM

$CGEM ✌️

0 · Reply

StardustTrader Oct. 16 at 2:06 PM

$CGEM should short this junk with AA at the helm

0 · Reply

SEC_official_Account Oct. 16 at 12:15 AM

$CGEM sold +11%

0 · Reply

stocksrtoohard Oct. 15 at 8:58 PM

$CGEM welp, hope someone got some more profits off her, will be looking to reposition after retest in coming days (hopefully) break and hold of 9.30-50 range will be where this run could go even bigger imo

0 · Reply

NEWBIGTECH Oct. 14 at 3:24 PM

$ACET $CGEM $CRWV

0 · Reply

Market Cap	431.83M
Revenue (ttm)	0.00
Net Income (ttm)	-167.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	712,000
Avg Vol	1,031,430
Day's Range	N/A - N/A
Shares Out	59.07M
Stochastic %K	17%
Beta	-0.07
Analysts	Strong Sell
Price Target	$26.88